BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31359452)

  • 1. Early Aβ reduction prevents progression of cerebral amyloid angiopathy.
    Schelle J; Wegenast-Braun BM; Fritschi SK; Kaeser SA; Jährling N; Eicke D; Skodras A; Beschorner N; Obermueller U; Häsler LM; Wolfer DP; Mueggler T; Shimshek DR; Neumann U; Dodt HU; Staufenbiel M; Jucker M
    Ann Neurol; 2019 Oct; 86(4):561-571. PubMed ID: 31359452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
    Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.
    van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM
    Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
    Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
    J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Levels of Cerebrospinal Fluid/Plasma Aβ40 as an Early Biomarker for Cerebral Amyloid Angiopathy in RTg-DI Rats.
    Zhu X; Xu F; Hoos MD; Lee H; Benveniste H; Nostrand WEV
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31906317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice.
    Herzig MC; Paganetti P; Staufenbiel M; Jucker M
    Neurodegener Dis; 2007; 4(2-3):127-35. PubMed ID: 17596707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis.
    Herzig MC; Winkler DT; Burgermeister P; Pfeifer M; Kohler E; Schmidt SD; Danner S; Abramowski D; Stürchler-Pierrat C; Bürki K; van Duinen SG; Maat-Schieman ML; Staufenbiel M; Mathews PM; Jucker M
    Nat Neurosci; 2004 Sep; 7(9):954-60. PubMed ID: 15311281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Origins of Beta Amyloid Differ Between Vascular Amyloid Deposition and Parenchymal Amyloid Plaques in the Spinal Cord of a Mouse Model of Alzheimer's Disease.
    Yuan Q; Liu X; Xian YF; Tang Y; Zou J; Zhang X; Huang P; Wu W; Song YQ; Lin ZX
    Mol Neurobiol; 2020 Jan; 57(1):278-289. PubMed ID: 31325023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
    de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
    Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
    Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM
    J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
    J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.
    Tanaka M; Saito S; Inoue T; Satoh-Asahara N; Ihara M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
    Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
    Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.
    Schultz AP; Kloet RW; Sohrabi HR; van der Weerd L; van Rooden S; Wermer MJH; Moursel LG; Yaqub M; van Berckel BNM; Chatterjee P; Gardener SL; Taddei K; Fagan AM; Benzinger TL; Morris JC; Sperling R; Johnson K; Bateman RJ; ; Gurol ME; van Buchem MA; Martins R; Chhatwal JP; Greenberg SM
    Ann Neurol; 2019 Oct; 86(4):616-625. PubMed ID: 31361916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
    Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
    Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
    Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
    J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy.
    Marazuela P; Solé M; Bonaterra-Pastra A; Pizarro J; Camacho J; Martínez-Sáez E; Kuiperij HB; Verbeek MM; de Kort AM; Schreuder FHBM; Klijn CJM; Castillo-Ribelles L; Pancorbo O; Rodríguez-Luna D; Pujadas F; Delgado P; Hernández-Guillamon M
    Acta Neuropathol Commun; 2021 Sep; 9(1):154. PubMed ID: 34530925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.